Home / Knowledge Centre /

Exploring Common Questions for Your EU Drug Product Launch

Launching a drug product in the EU has many nuanced regulatory strategy considerations that a biopharmaceutical company must keep in mind while planning a launch. Proactively considering these procedures and adequately preparing for what will be needed prior to starting the process is crucial to ensure the most efficient and cost-effective process with minimum risk.
Brian Lavery, Regulatory Affairs Lead at Almac Pharma Services discusses the most common questions when launching your drug product with International Clinical Trials.

View Resource

Please complete this form to view the Article

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies